Etiological Role of Sulfate-Reducing Bacteria in the Development of Inflammatory Bowel Diseases and Ulcerative Colitis

Ivan V. Kushkevych^1,

¹Laboratory of Molecular Biology and Clinical Biochemistry, Institute of Animal Biology of NAAS of Ukraine, Lviv, Ukraine

Cite this paper:
Ivan V. Kushkevych. Etiological Role of Sulfate-Reducing Bacteria in the Development of Inflammatory Bowel Diseases and Ulcerative Colitis. American Journal of Infectious Diseases and Microbiology. 2014; 2(3):63-73. doi: 10.12691/ajidm-2-3-5

Abstract

Inflammatory bowel disease and ulcerative colitis are complex multifactorial diseases of unknown etiology. The etiological role of the sulfate-reducing bacteria Desulfovibrio piger Vib-7 and Desulfomicrobium sp. Rod-9 in the development of these inflammatory diseases in rats was studied. Applying sulfate-reducing bacteria, ulcerative colitis in the animals was experimentally induced at the fist time. In total 45 animals in three groups were separated and used in this experiment. Animals in the first group received the standard diet containing a special certified feed for rats and were used as a control. The second group received the standard feed and a dose (1 ml per each day) of modified Kravtsov-Sorokin's liquid medium for the initiation of own potential animal intestinal microflora of sulfate-reducing bacteria. The third group of the animals received the standard feed and dose of a suspension with D. piger Vib-7 and Desulfomicrobium sp. Rod-9 (at a ratio of 1 to 1) in the medium. The changes in the colonic microbiota under these conditions were studied. The bacteria belonging to the normal colonic microbiota were associated with the etiology of inflammatory bowel disease and ulcerative colitis. The concentration of sulfide and acetate in feces from different sections of the large intestine of the rats was determined. The level of ulcerations in the second and third groups of sick animals under the specific conditions was demonstrated. The described experimental results could be particularly useful for the study of inflammatory bowel disease and ulcerative colitis and its therapeutic strategy. These data are also indispensable to apply into mechanistic details that will facilitate better preclinical drug/therapy design to target specific components involved in the disease pathogenesis.

Keywords:
sulfate-reducing bacteria sulfide acetate inflammatory bowel diseases ulcerative colitis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Barton, L.L. and Hamilton, W.A., Sulphate-Reducing Bacteria. Environmental and Engineered Systems, Cambridge University Pres, Cambridge, 2010, 553 p.
[2]	Gibson, G.R., Cummings, J.H., Macfarlane, G.T., “Growth and activities of sulphate-reducing bacteria in gut contents of health subjects and patients with ulcerative colitis”, FEMS Microbiol Ecol, 86. 103-112. 1991.
[3]	Gibson, G.R., Macfarlane, G.T., Cummings, J.H., “Sulphate-reducing bacteria and hydrogen metabolism in the human large intestine”, Gut, 34. 437-439. 1993.
[4]	Kushkevych, I.V., “Sulfate-reducing bacteria of the human intestine. I. Dissimilatory sulfate reduction”, Sci Int J Biological studies/Studia Biologica, 6(1). 149-180. 2012.
[5]	Brenner, D.J., Krieg, N.R., Staley, J.T., Garrity, G.M. Bergey’s manual of Systematic Bacteriology. The Proteobacteria, Part C: The Alpha-, Beta-, Delta-, and Epsilonproteobacteria. Second Edition. Printed in the United States of America, 1388 p. 2005.
[6]	Postgate, J.R., The sulfate-reducing bakteria, Cambridge University Press, Cambridge, 1984, 199 p.
[7]	Gibson, G.R., Macfarlane, S., Macfarlane, G.T., “Metabolic interactions involving sulphate-reducing and methanogenic bacteria in the human large intestine”, FEMS Microbiol Ecol, 12. 117-125. 1993.
[8]	Kushkevych, I.V., “Sulfate-reducing bacteria of the human intestine. II. The role in the diseases development”, Sci Int J Biological studies/Studia Biologica, 6(2). 221-250. 2012.
[9]	Kushkevych, I.V. and Moroz, O.M., “Growth of various strains of sulfate-reducing bacteria of human large intestine”, Sci Int J Biological studies/Studia Biologica, 6(3). 107-116. 2012.
[10]	Macfarlane, S., Hopkins, M.J., Macfarlane, G.T., “Bacterial growth and metabolism on surfaces in the large intestine”, Microb Ecol Health Dis, 2. 64-72. 2000.
[11]	Levine, J., Ellis, C.J., Furne, J.K., Springfield, J. and Levitt, M.D., “Fecal Hydrogen Sulfide Production in Ulcerative Colitis”, The American J Gastroenterol, 93(1). 83-87. 1998.
[12]	Loubinoux, J., Bronowicji, J.-P., Pereira, I.A. et al., “Sulphate-reducing bacteria in human feces and their association with inflammatory diseases”, FEMS Microbiol Ecol, 40. 107-112. 2002.
[13]	Loubinoux, J., Mory, F., Pereira, I.A. et al., “Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis”, J Clin Microbiol, 38. 931-934. 2000.
[14]	Pitcher, M.C., Cummings, J.H., “Hydrogen sulphide: a bacterial toxin in ulcerative colitis?”, Gut, 39. 1-4. 1996.
[15]	Pitcher, M.C.L., Beatty, E.R., Gibson, G.R., et al., “Incidence and activities of sulphate-reducing bacteria in patients with ulcerative colitis”, Gut, 36. A63 (abstract). 1995.
[16]	Macfarlane, S. and Dillon, J.F., “Microbial biofilms in the human gastrointestinal tract”, J Appl Microbiol, 102. 1187-1196. 2007.
[17]	Zinkevich, V.V., Beech, I.B. “Screening of sulfate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa”, FEMS Microbiol. Ecol, 34. 147-155. 2000.
[18]	Sekirov, I., Russell, S.L., Antunes, L.C.M., Finlay, B.B., “Gut Microbiota in Health and Disease”, Physiol Rev, 90. 859-904. 2010.
[19]	Cummings, J.H., Macfarlane, G.T., Macfarlane, S., “Intestinal Bacteria and Ulcerative Colitis”, Curr Issues Intest Microbiol, 4. 9-20. 2003.
[20]	Levitt, M.D., Furne, J., Springfield, J., Suarez, F. and Demaster, E., “Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa”, J Clin Invest, 104. 1107-1114. 1999.
[21]	Florin, T.H.J., Gibson, G.R., Neale, G. et al., “A role for sulfate reducing bacteria in ulcerative colitis?”, Gastroenterology, 98. A170 (abstract). 1990.
[22]	Perse, M. and Cerar, A., “Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks”, J Biomed and Biotech, Article ID 718617. 1-13. (2012).
[23]	Low, D., Nguyen, D.D., Mizoguchi, E., “Animal models of ulcerative colitis and their application in drug research”, Drug Design, Development and Therapy, 7. 1341-1357. 2013.
[24]	Zheng, L., Gao, Z.Q. and Wang, S.X., “A chronic ulcerative colitis model in rats”, World Journal of Gastroenterology, 6(1). 150-152. 2000.
[25]	Nell, S., Suerbaum, S., Josenhans, C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models, Nat Rev Microbiol, 8(8). 564-577. 2010.
[26]	Kushkevych, I.V., “Identification of sulfate-reducing bacteria strains of human large intestine”, Sci Int J Biological studies/Studia Biologica, 7(3). 115-124. 2013.
[27]	Kushkevych, I.V., Bartos, M., Bartosova, L., “Sequence analysis of the 16S rRNA gene of sulfate-reducing bacteria isolated from human intestine”, Int J Curr Microbiol Appl Sci, 3(2). 239-248. 2014.
[28]	Ohge, H., Furne, J.K., Springfield, J., Sueda, T., Madoff, R.D., Levitt, M.D., “The effect of antibiotics and bismuth on fecal hydrogen sulfide and sulfate-reducing bacteria in the rat”, FEMS Microbiol Lett, 228. 137-142. 2003.
[29]	Levitt, M.D., Springfield, J., Furne, J., Koenig, T. and Suarez, F., “Physiology of sulfide in the rat colon: use of bismuth to assess colonic sulfide production”, J Appl Physiol, 92. 1655-1660. 2002.
[30]	Bailey, N.T.J. Statistical Methods in Biology, Cambridge University Press, Cambridge, 1995, 252 p.
[31]	Chen, P.Y., Popovich, P.M., Correlation: Parametric and Nonparametric Measures. Sage University Papers Series on Quantitative Applications in the Social Sciences, 2002, 104 p.
[32]	Beauchamp, R.O., Bus, J.S., Popp, J.A., Boreiko, C.J. and Andjelkovich, D.A., “A critical review of the literature on hydrogen sulfide toxicity”, Crit Rev Toxicol, 13. 25-97. 1984.
[33]	Suarez, F.L., Furne, J., Springfield, J. and Levitt, M.D., “Production and elimination of sulfur-containing gases in the rat colon”, Am J Physiol, 274. G727-G733. 1998.
[34]	Chapman, M.A.S., Grahn, M.F., Boyle, M.A. et al., “Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis”, Gut, 35. 73-76. 1994.
[35]	Roediger, W.E.W., Duncan, A., Kapaniris, O. and Millard, S. “Reducing sulfur compounds of colon impair colonocyte nutrition: implications for ulcerative colitis”, Gastroenterology, 104. 802-809. 1993.
[36]	Roediger, W.E.W., Duncan, A., Kapaniris, O., et al., “Sulphide impairment of substrate oxidation in rat colonocytes: A biochemical basis for ulcerative colitis?”, Clin Sci, 85. 623-627. 1993.
[37]	Roediger, W.E.W., Nance, S., “Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation”, Br J Exp Pathol, 67. 773-782. 1986.
[38]	Sax, N.I., Dangerous properties of industrial materials. Van Nostrand Reinhold Company, New York, 1984.
[39]	Vogt, J.A. and Wolever, T.M.S., “Fecal Acetate Is Inversely Related to Acetate Absorption from the Human Rectum and Distal Colon”, J Nutr, 133(10). 3145-3148. 2003.
[40]	Walmsey, R.S., Anthony, A., Slim, R., et al., “Absence of Escherichia coli, Listeria moncytogenes, and Klebsiella pneumonae antigens within inflammatory bowel disease tissues”, J Clin Pathol, 51. 657-661. 1998.
[41]	Kallinowski, F., Wassmer, A., Hofmann, M.A., et al., “Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease”, Hepatogastroenterology, 45. 1552-1558. 1998.
[42]	Campieri, M., and Gionchetti, P., “Bacteria as the cause of ulcerative colitis”, Gut, 48. 132-135. 2001.
[43]	Burke, D.A., Axon, A.T.R., “Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea”, BMJ, 297. 102-104. 1988.
[44]	Burke, D.A., Axon, A.T.R., “Ulcerative colitis and Escherichia coli with adhesive properties”, J Clin Pathol, 40. 782-786. 1987.
[45]	Schultsz, C., Moussa, M., van Ketel, R., et al., “Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls”, J Clin Pathol, 50. 573-579. 1997.
[46]	Von Wulffen, H, Rüssmann, H., Karch, H., et al., “Verocytoxin-Producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis”, Lancet; 1. 1449-1450. 1989.
[47]	Schultsz, C., van den Berg, F.M., Ten Kate F.W. et al., “The intestinal mucus layer from patients with inflammatory bowel disease harbours numbers of bacteria compared with controls”, Gastroenterology, 117. 1089-1097. 1999.
[48]	Onderdonk, A.B., Bronson, R., Cisneros, R., “Comparison of bacteroides vulgatus strains in the enhancement of experimental ulcerative colitis”, Infect Immun, 55. 835-836. 1987.
[49]	Rath, H.C., Ikeda, J.S., Linde. H.-J., et al., “Varying caecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats”, Gastroenterology, 116. 310-319. 1999.
[50]	Ehrhardt, R.O., Lúdvíksson, B.R., Gray, B., et al., “Induction and prevention of colonic inflammation in IL-2-deficient mice”, J Immunology, 158. 566-573. 1997.
[51]	Kuhn, R., Lohler, J., Rennick, D., et al., Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 75. 263-274. 1993.
[52]	Fite, A., Macfarlane, S., Furrie, E. et al., “Longitudinal Analyses of Gut Mucosal Microbiotas in Ulcerative Colitis in Relation to Patient Age and Disease Severity and Duration”, J Clin Microbiol, 51(3). 849-856. 2013.
[53]	Rowan, F.E., Docherty, N.G., Coffey, J.C. et al., “Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis”, British J Surgery, 96. 151-158. 2009.
[54]	Barnett, M. and Fraser, A. “Animal Models of Colitis: Lessons Learned, and Their Relevance to the Clinic”, Ulcerative Colitis, 161-178. 2011.